Cancer causes anemia through at least six distinct mechanisms, and in some cases, anemia is the first sign that a malignancy exists. Studies show that 30–90% of cancer patients develop anemia at some point during their disease, with rates varying by cancer type, stage, and treatment. If you’re trying to understand the connection between how cancers cause anemia, the short answer is: cancers disrupt red blood cell production, increase red blood cell destruction, or cause blood loss — and many cancers do all three simultaneously.
This isn’t just a lab abnormality. Cancer-related anemia independently worsens survival, reduces quality of life, and limits treatment options. A hemoglobin below 10 g/dL in a cancer patient is associated with increased fatigue severe enough to affect daily functioning, and hemoglobin below 8 g/dL often triggers transfusion discussions. Recognizing why a cancer patient is anemic changes how you treat them.
The 6 Ways Cancer Causes Anemia
Not all cancer-related anemia is the same. The mechanism matters because it determines the treatment. Here’s a breakdown of the six primary pathways:
1. Anemia of Chronic Disease (ACD)
This is the most common mechanism. Tumors trigger an inflammatory response, releasing cytokines like IL-6, TNF-alpha, and interferon-gamma. These cytokines stimulate the liver to produce hepcidin, a hormone that blocks iron absorption from the gut and traps iron inside macrophages. The result: plenty of iron in storage (ferritin is often normal or elevated), but the bone marrow can’t access it to make red blood cells.
ACD is especially common in solid tumors like lung, breast, and colorectal cancers. The hemoglobin typically sits in the 8–10 g/dL range, and the anemia is usually normocytic (normal-sized red blood cells with an MCV of 80–100 fL).
2. Bone Marrow Infiltration (Myelophthisis)
Some cancers physically invade the bone marrow and crowd out normal blood-forming cells. Leukemias, lymphomas, multiple myeloma, and metastatic solid tumors (especially breast, prostate, and lung) are the usual culprits. A peripheral blood smear showing teardrop cells, nucleated red blood cells, and immature white cells — a pattern called a leukoerythroblastic picture — is the classic clue.
3. Blood Loss
Gastrointestinal cancers are notorious for causing chronic, occult bleeding. Colorectal cancer is the textbook example — iron deficiency anemia in an adult over 50 should prompt colonoscopy. Gastric cancer, esophageal cancer, and bladder cancer can also cause significant blood loss. This produces a microcytic, iron-deficient anemia with low ferritin (typically <15 ng/mL) and low serum iron.
4. Hemolysis
Certain cancers trigger the immune system to destroy red blood cells prematurely. Autoimmune hemolytic anemia (AIHA) occurs in roughly 5–10% of patients with chronic lymphocytic leukemia (CLL) and in some lymphomas. Labs show elevated LDH, low haptoglobin, elevated indirect bilirubin, and a positive direct Coombs test. Microangiopathic hemolytic anemia (MAHA) — with schistocytes on smear — can occur with mucin-secreting adenocarcinomas, particularly gastric cancer.
5. Nutritional Deficiency
Cancer causes anorexia, malabsorption, and increased metabolic demands. Folate and B12 deficiencies are common in GI malignancies, producing macrocytic anemia (MCV >100 fL). Surgery — especially gastrectomy or ileal resection — can permanently impair nutrient absorption.
6. Treatment-Related Anemia
Chemotherapy, particularly platinum-based regimens (cisplatin, carboplatin), directly suppresses erythropoiesis. Radiation to large marrow-bearing bones (pelvis, spine) does the same. Roughly 50–60% of patients receiving chemotherapy develop clinically significant anemia.
Which Cancers Cause Anemia Most Often?
| Cancer Type | Prevalence of Anemia | Primary Mechanism(s) |
|---|---|---|
| Lung cancer | 50–70% | ACD, chemotherapy |
| Colorectal cancer | 30–67% | Chronic blood loss, iron deficiency |
| Multiple myeloma | 70–80% | Marrow infiltration, renal impairment |
| Leukemia (acute) | ~90% | Marrow infiltration |
| CLL | 30–40% at diagnosis | Marrow infiltration, AIHA |
| Gastric cancer | 40–60% | Blood loss, B12 deficiency, MAHA |
| Ovarian/gynecologic | 50–60% | ACD, chemotherapy, blood loss |
Key Lab Values That Help Identify the Cause
When a cancer patient presents with anemia, the following labs help distinguish the mechanism:
| Lab Test | Iron Deficiency (Blood Loss) | Anemia of Chronic Disease | Hemolysis | Marrow Infiltration |
|---|---|---|---|---|
| MCV | Low (<80 fL) | Normal (80–100 fL) | Normal to high | Variable |
| Ferritin | Low (<15 ng/mL) | Normal to high (>100 ng/mL) | Normal to high | Variable |
| TIBC | High | Low | Normal | Normal |
| Reticulocyte count | Appropriately elevated | Low (inadequate response) | Elevated | Low |
| LDH | Normal | Normal | Elevated | May be elevated |
| Haptoglobin | Normal | Normal | Low/absent | Normal |
| Peripheral smear | Microcytic, hypochromic | Normocytic | Schistocytes or spherocytes | Leukoerythroblastic |
The Role of Neuraminidases: An Emerging Mechanism
Recent research has identified another layer to cancer-related anemia. Some tumors — particularly hepatocellular carcinoma — secrete neuraminidases, enzymes that strip sialic acid residues from the surface of red blood cells. Sialic acid acts as a “don’t eat me” signal to the spleen. Without it, red blood cells are flagged for destruction by splenic macrophages, accelerating their clearance from circulation.
This mechanism may partially explain why some cancer patients develop anemia out of proportion to what their iron studies, marrow biopsies, or bleeding assessments would predict. Research in this area is still evolving, but it represents a potentially targetable pathway for future therapies.
When to See a Doctor
If you have cancer and experience any of the following, bring it up with your oncologist promptly:
- New or worsening fatigue that limits daily activities
- Shortness of breath with minimal exertion (climbing one flight of stairs, walking across a room)
- Dizziness, lightheadedness, or near-fainting episodes
- Heart racing at rest (resting heart rate consistently above 100 bpm)
- Unusually pale skin, nail beds, or gums
- Dark or tarry stools, or visible blood in urine
If you don’t have a cancer diagnosis but have unexplained iron deficiency anemia — especially if you’re over 50 — ask your doctor about cancer screening. Iron deficiency anemia in a postmenopausal woman or any adult male should be considered GI cancer until proven otherwise.
Frequently Asked Questions
Can anemia be the first sign of cancer?
Yes. In colorectal cancer especially, iron deficiency anemia is frequently the presenting symptom — sometimes months before any GI symptoms appear. Guidelines in the UK (NICE) recommend urgent referral for colonoscopy in anyone over 60 with iron deficiency anemia even without GI symptoms.
What hemoglobin level is dangerous in cancer patients?
There’s no single cutoff, but most oncologists become concerned below 10 g/dL and consider transfusion below 7–8 g/dL, depending on symptoms and comorbidities. A hemoglobin below 7 g/dL with symptoms (chest pain, severe dyspnea, tachycardia) typically warrants urgent transfusion.
Does treating the cancer fix the anemia?
Often, yes — if the cancer is the primary driver. Successful chemotherapy for leukemia can restore normal marrow function. Resecting a bleeding colon tumor stops the blood loss. However, many chemotherapy regimens worsen anemia in the short term before things improve, and some patients need erythropoiesis-stimulating agents (ESAs) or IV iron during treatment.
Is cancer-related anemia treated differently than regular anemia?
It depends on the mechanism. Simple iron deficiency from blood loss responds to IV iron. Anemia of chronic disease often doesn’t respond well to oral iron (because the problem is iron trapping, not iron deficiency). ESAs like epoetin alfa or darbepoetin may be used, but they carry risks including thromboembolism and are typically reserved for chemotherapy-induced anemia with hemoglobin below 10 g/dL.
Can anemia make cancer treatment less effective?
Yes. Anemia causes tumor hypoxia, which can reduce the effectiveness of radiation therapy (oxygen enhances radiation-induced DNA damage). Severe anemia may also force chemotherapy dose reductions or delays, both of which compromise outcomes. Multiple studies have shown that anemic cancer patients have worse overall survival independent of cancer stage.
